Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Two trends appear to be working against Moderna right now.

1 Picture That Sums Up Moderna's Biggest Problem

Moderna Inc. MRNA, +0.71% said Monday the Japanese regulator has approved a partial change to its new drug application for its omicron-targeting COVID booster, MRNA-1273.214. The approval from the Ministry of Health, Labour and Welfare is based on data from a Phase 2/3 trial in which the booster met all primary endpoints, including superior neutralizing antibody response against omicron compared to the currently approved dose of Spikevax in previously uninfected trial participants.

Moderna says Japan regulator has approved partial change to NDA for its omicron-targeting COVID booster

CAMBRIDGE, MA / ACCESSWIRE / September 12, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial change to a new drug application for its Omicron-targeting bivalent COVID-19 booster, mRNA-1273.214 (Spikevax Bivalent Original/Omicron BA.1). Spikevax Bivalent Original/Omicron contains mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant BA.1.

Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214

Moderna's recent prediction should lift one of investors' biggest fears.

This 1 Number Could Completely Change Your Opinion of Moderna

A prognosticator is particularly hopeful for the company's planned triple vaccine.

Why Moderna Stock Triumphed on Thursday

Novavax

Pfizer

Pfizer, Moderna, and Novavax all had a rough month in August.

Here's Why These Top 3 COVID-19 Vaccine Stocks Broke Down in August

Vaccine maker Moderna Inc's chief commercial officer (CCO) said on Thursday that the size of the future COVID-19 vaccine market in the United States could be in the range of $5.2 billion to $12.9 billion, depending on the price of shots and who is eligible to receive them.

U.S. COVID-19 vaccine market could be up to $13 billion-Moderna exec

Put options are a way to generate yield with downside protection. MRNA's high volatility makes selling options more attractive.

Put Option Strategy To Generate 11.2% Yield On Cash Or Own Moderna At $82

Repligen

These companies bring different strengths and opportunities to a stock portfolio.

2 Top Healthcare Stocks to Buy for September

Moderna Inc  (NASDAQ:MRNA) received an upgrade from Deutsche Bank to "buy" from "hold" this morning, as well as a price-target hike to $165 from $155.

Moderna Stock Moves Higher on Upgrade to "Buy"

Interim data from Phase 1/2 propionic acidemia (PA) multi-dose Paramount trial shows mRNA-3927 was well-tolerated to date, with encouraging early signs of potential for clinical benefit Interim data from Phase 1/2 glycogen storage disease 1a (GSD1a) single-dose Ba1ance trial shows mRNA-3745 was well tolerated to date, with encouraging early signs of potential for clinical benefit Moderna announces a new development candidate, mRNA-3139, for ornithine transcarbamylase (OTC) deficiency, a rare genetic disorder Phase 3 clinical trial of RSV vaccine, mRNA-1345, has enrolled more than 24,000 of the 34,000-participant target Phase 3 immunogenicity and safety study of flu vaccine, mRNA-1010, is fully enrolled; Company to pursue accelerated approval pathway in 2023 Company is on track to report data from its Phase 2 personalized cancer vaccine (PCV) study in 4Q 2022 CAMBRIDGE, MA / ACCESSWIRE / September 8, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced advances across its portfolio of mRNA programs presented at the Company's annual R&D Day. "We continue to make significant progress in accelerating our pipeline.

Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day

New vaccine guidelines by U.S. health authorities may dampen sales of the biotech's top coronavirus vaccine.

Why Moderna Stock Slumped Today

CAMBRIDGE, MA / ACCESSWIRE / September 6, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Stephen Hoge, M.D., President, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13th at 10:00 a.m.

Moderna to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

It looks like there will be plenty of Covid vaccines available for a fall and winter surge, but once the money in the current program runs out, the U.S. government won't be paying for them.

Shifting Covid Vaccine Coverage to Private Payers Is Good for Moderna, Pfizer

MRNA has fallen nearly 30% from its August highs, as it got rejected by the $200 resistance level again. As a result, we urged investors to be cautious in July. Investors need to be wary about Moderna's ability to sustain its revenue visibility post-FY22, as its growth cadence from its COVID vaccines is expected to decline.

Moderna: Patient Investors Are Given Another Fantastic Buy Point On The Pullback

Apple

Cross Country Healthcare

Dick's Sporting Goods

NVIDIA

O'Reilly Automotive

Perficient

MarketWatch published an article early in 2022 which highlighted last year's  best-performing S&P 500, mid-cap, small-cap, Nasdaq-100, and Dow 30 stocks. Some of the names on the five lists were cited by analysts as the top growth stocks to buy in 2022.

7 Growth Stocks That Could 10X by 2027

Moderna (MRNA) reported earnings 30 days ago. What's next for the stock?

Moderna (MRNA) Down 28.4% Since Last Earnings Report: Can It Rebound?

BioNTech SE

Pfizer (PFE) /BioNTech (BNTX) and Moderna (MRNA) get positive CHMP opinion for Omicron-targeting bivalent booster.

PFE, BNTX and MRNA Omicron Boosters Get Positive CHMP Opinion

The CDC green-lighted updated Covid boosters from Pfizer and Moderna, helping vaccine stocks edge higher Friday. The post Moderna, BioNTech Jump After CDC Green-Lights Updated Covid Boosters appeared first on Investor's Business Daily.

Moderna, BioNTech Jump After CDC Green-Lights Updated Covid Boosters

Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) develop the Omicron BA.4/BA.5-adapted bivalent vaccines at the FDA's recommendation.

FDA Authorizes Pfizer, Moderna's Omicron-Based Boosters

mRNA-1273.214 is the first Omicron-targeting bivalent COVID-19 booster vaccine approved in Canada Study results show mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 subvariants when compared with mRNA-1273 Approval follows agreement with the Government of Canada to supply 12 million doses of Omicron-targeting bivalent COVID-19 boosters CAMBRIDGE, MA / ACCESSWIRE / September 1, 2022 / Moderna, Inc . (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Health Canada has authorized the use of its Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.214 (Spikevax Bivalent Original/Omicron) as a booster dose for active immunization against COVID-19 caused by the SARS-CoV-2 virus in individuals 18 years of age and older.

Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Booster Vaccine

Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Moderna (MRNA) Stock?

Study results show mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 subvariants when compared with mRNA-1273 Positive recommendation follows recent amendment to European Commission (EC) COVID-19 vaccine agreement to supply Omicron-targeting bivalent candidates In addition to the CHMP positive opinion, Moderna has received approvals for mRNA-1273.214 in Australia, Switzerland, and the UK CAMBRIDGE, MA / ACCESSWIRE / September 1, 2022 / Moderna, Inc . (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization for Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214), the company's next-generation bivalent vaccine candidate that contains mRNA-1273 and a vaccine candidate targeting the Omicron variant of concern (BA.1).

EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of Moderna's Omicron-Targeting Bivalent Booster in the European Union

Good news for the world lowers bullishness on the company's future.

Why Moderna Stock Slumped on Wednesday

New boosters from Moderna and Pfizer may be given out in the coming days, pending approval from the CDC.

News for Moderna Stock (MRNA)